| Real‐world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: a study of the Greco … E Katodritou, E Kastritis, M Gatt, YC Cohen, I Avivi, A Pouli, C Lalayianni, ... American Journal of Hematology 95 (5), 465-471, 2020 | 12 | 2020 |
| Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: a multicenter study by the Greek myeloma study group E Katodritou, E Kastritis, D Dalampira, S Delimpasi, E Spanoudakis, ... American Journal of Hematology 98 (5), 730-738, 2023 | 3 | 2023 |
| Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group E Katodritou, D Dalampira, S Delimpasi, I Ntanasis-Stathopoulos, ... Blood 142, 1981, 2023 | 1 | 2023 |
| Circulating miR-16 and miR-21 Levels in Multiple Myeloma: Prognostic Significance of Survival and Response to Lenalidomide Treatment AI Gkioka, M Tsota, A Koudouna, A Gkiokas, CA Mitropoulou, ... International Journal of Molecular Sciences 25 (11), 6065, 2024 | | 2024 |
| Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy A Koudouna, AI Gkioka, A Gkiokas, TM Tryfou, M Papadatou, ... International Journal of Molecular Sciences 25 (5), 2862, 2024 | | 2024 |
| Serum Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy MC Kyrtsonis, A Koudouna, AI Gkioka, A Gkiokas, V Bartzi, ... Preprints, 2024 | | 2024 |
| Soluble CD163; A Possible New Biomarker in Multiple Myeloma AI Gkioka, A Gkiokas, A Alexandropoulos, M Papadatou, A Koudouna, ... Blood 142, 3373, 2023 | | 2023 |
| P-192 Increased serum CRBN levels are associated with improved survival in MM patients AI Gkioka, A Gkiokas, M Papadatou-Gigante, A Alexandropoulos, ... Clinical Lymphoma Myeloma and Leukemia 23, S141, 2023 | | 2023 |
| PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS AI Gkioka, A Gkiokas, A Alexandropoulos, M Papadatou, A Koudouna, ... HemaSphere 7 (S3), e35250bc, 2023 | | 2023 |
| INCREASED SOLUBLE SERUM CD163 (SCD163) LEVELS PREDICT A SHORT DISEASE FREE SURVIVAL IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). A Koudouna, A Gkioka, A Alexandropoulos, T Tryfou, M Papadatou, ... Hematological Oncology 41, 2023 | | 2023 |
| SOLUBLE SERUM CD163 (SCD163) LEVELS IS A MARKER OF DISEASE ACTIVITY IN LYMPHOPLASMACYTIC LYMPHOMA (LPL). PRELIMINARY RESULTS. A Gkiokas, A Gkioka, M Papadatou, T Tryfou, V Bartzi, A Koudouna, ... Hematological Oncology 41, 2023 | | 2023 |
| Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group E Katodritou, E Kastritis, D Dalampira, S Delimpasi, E Spanoudakis, ... Blood 140 (Supplement 1), 4386-4387, 2022 | | 2022 |
| P-174: Validation of Mayo Clinic 2018 and IMWG 2020 prognostic risk score for smoldering multiple myeloma (SMM), real world data; single center experience A Gkiokas, AI Gkioka, M Papadatou, A Alexandropoulos, V Bartzi, ... Clinical Lymphoma Myeloma and Leukemia 22, S130-S131, 2022 | | 2022 |
| PB1957: CIRCULATING MIRNA-16 AND MIRNA-21 EXPRESSION LEVELS IN MYELOMA; PRELIMINARY RESULTS. AI Gkioka, M Tsota, M Papadatou, A Gkiokas, A Alexandropoulos, V Bartzi, ... HemaSphere 6, 1830-1831, 2022 | | 2022 |
| P-085: Updated outcomes on Lenalidomide (Len) refractory MM patients’ AI Gkioka, M Papadatou, A Gkiokas, A Koudouna, V Bartzi, A Bitsani, ... Clinical Lymphoma Myeloma and Leukemia 21, S85-S86, 2021 | | 2021 |
| Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients AI Gkioka, A Koudouna, V Bartzi, M Dimou, T Iliakis, A Bitsani, V Pardalis, ... Blood 136, 15-16, 2020 | | 2020 |
| Lenalidomide (Len) Refractory MM Patients’ Outcomes AI Gkioka, P Repousis, N Rougkala, E Asmanis, V Bartzi, M Dimou, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e160-e161, 2019 | | 2019 |
| Prognostic value and clinical correlations of serum cereblon (CRBN) levels in multiple myeloma patients treated with Lenalidomide/Dexamethasone (RD). AI Gkioka, P Repousis, P Papaioannou, T Tryfou, N Rougkala, M Dimou, ... Clinical Lymphoma, Myeloma and Leukemia 19 (10), e117, 2019 | | 2019 |
| PB1895 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH INCREASED SERUM VON WILLEBRAND LEVELS AT DIAGNOSIS HAVE A SHORTER TIME TO TREATMENT P Papaioannou, P Repousis, AI Gkioka, E Koulieris, S Sachanas, ... HemaSphere 3 (S1), 863-864, 2019 | | 2019 |
| PF627 SERUM CEREBLON LEVELS PREDICT FIVE-YEAR POST LEALIDOMIDE/DEXAMETHASONE (RD) SURVIVAL IN MULTIPLE MYELOMA (MM) PATIENTS AND CORRELATE WITH DISEASE CHARACTERISTICS AI Gkioka, P Papaioannou, R Niki, M Dimou, I Theodoros, V Pardalis, ... HemaSphere 3 (S1), 267, 2019 | | 2019 |
